Rani Therapeutics logo

Rani Therapeutics Share Price Today

(NASDAQ: RANI)

Rani Therapeutics share price is $1.54 & ₹133.93 as on 6 Mar 2025, 2.30 'hrs' IST

$1.54

0.11

(7.69%)

Market is closed - opens 8 PM, 06 Mar 2025

View live Rani Therapeutics share price in Dollar and Rupees. Guide to invest in Rani Therapeutics stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Rani Therapeutics, along with analyst recommendations, forecasts, and comprehensive financials.

Rani Therapeutics share price movements

  • Today's Low: $1.44
    Today's High: $1.54

    Day's Volatility :6.49%

  • 52 Weeks Low: $1.24
    52 Weeks High: $8.75

    52 Weeks Volatility :85.83%

Rani Therapeutics (RANI) Returns

PeriodRani Therapeutics Holdings IncIndex (Russel 2000)
3 Months
-22.7%
0.0%
6 Months
-47.62%
0.0%
1 Year
-61.46%
0.0%
3 Years
-89.96%
-11.6%

Rani Therapeutics (RANI) Key Statistics

in dollars & INR

Previous Close
$1.43
Open
$1.45
Today's High
$1.54
Today's Low
$1.44
Market Capitalization
$86.1M
Today's Volume
$7.2K
52 Week High
$8.75
52 Week Low
$1.24
Revenue TTM
$0.0
EBITDA
$-50.8M
Earnings Per Share (EPS)
$-1.06
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-270.57%

How to invest in Rani Therapeutics Stock (RANI) from India?

It is very easy for Indian residents to invest directly in Rani Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Rani Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Rani Therapeutics or RANI on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Rani Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Rani Therapeutics shares which would translate to 0.565 fractional shares of Rani Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Rani Therapeutics, in just a few clicks!

Returns in Rani Therapeutics (RANI) for Indian investors in Rupees

The Rani Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Rani Therapeutics investment value today

Current value as on today

₹46,472

Returns

₹53,528

(-53.53%)

Returns from Rani Therapeutics Stock

₹58,491 (-58.49%)

Dollar Returns

₹4,963 (+4.96%)

Indian investors sentiment towards Rani Therapeutics (RANI)

100%

Period: Feb 3, 2025 to Mar 5, 2025. Change in 30 Days versus previous period

Search interest for Rani Therapeutics Stock from India on INDmoney has increased by 100% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Rani Therapeutics

  • Vanguard Group Inc

    2.13%

  • Alphabet Inc

    1.35%

  • United Services Automobile Association

    0.91%

  • Two Sigma Investments LLC

    0.87%

  • Geode Capital Management, LLC

    0.52%

  • KESTRA PRIVATE WEALTH SERVICES, LLC

    0.36%

Analyst Recommendation on Rani Therapeutics

Buy

    92%Buy

    7%Hold

    0%Sell

Based on 13 Wall street analysts offering stock ratings for Rani Therapeutics(by analysts ranked 0 to 5 stars)

Based on 13 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
12
12
13
Hold
1
1
1
Sell
0
0
0

Analyst Forecast on Rani Therapeutics Stock (RANI)

What analysts predicted

Upside of 646.75%

Target:

$11.50

Current:

$1.54

Insights on Rani Therapeutics Stock (Ticker Symbol: RANI)

  • Price Movement

    In the last 6 months, RANI stock has moved down by -47.6%
  • RANI vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 62.3% return, outperforming this stock by 124.2%
  • RANI vs VRTX (3 yr)

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 47.7% return, outperforming this stock by 138.6%

Rani Therapeutics Technicals Summary

Sell

Neutral

Buy

Rani Therapeutics is currently in a neutral trading position according to technical analysis indicators.

Rani Therapeutics (RANI) Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Rani Therapeutics Holdings Inc logo
5.15%
-47.62%
-61.46%
-89.96%
-87.0%
Regeneron Pharmaceuticals, Inc. logo
1.3%
-41.29%
-30.51%
9.2%
42.38%
Beone Medicines Ltd logo
15.19%
34.31%
61.3%
43.16%
68.1%
Vertex Pharmaceuticals Incorporated logo
3.37%
3.77%
18.06%
106.43%
121.36%
Alnylam Pharmaceuticals, Inc. logo
-11.52%
-3.4%
62.32%
49.04%
120.93%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Rani Therapeutics Holdings Inc logo
NA
NA
NA
-1.01
-2.71
-0.57
NA
0.11
Regeneron Pharmaceuticals, Inc. logo
17.85
17.85
1.03
43.09
0.16
0.07
0.01
273.57
Beone Medicines Ltd logo
NA
NA
NA
1.43
-0.19
-0.06
NA
31.22
Vertex Pharmaceuticals Incorporated logo
32.84
NA
1.33
18.07
-0.03
0.13
NA
63.87
Alnylam Pharmaceuticals, Inc. logo
NA
NA
-0.49
0.57
-15.01
-0.03
NA
0.52
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Rani Therapeutics Holdings Inc logo
Buy
$86.1M
-87.0%
NA
0.0%
Regeneron Pharmaceuticals, Inc. logo
Buy
$74.9B
42.38%
17.85
31.07%
Beone Medicines Ltd logo
NA
$28.5B
68.1%
NA
-16.92%
Vertex Pharmaceuticals Incorporated logo
Buy
$124.1B
121.36%
32.84
-4.86%
Alnylam Pharmaceuticals, Inc. logo
Buy
$31.5B
120.93%
NA
-12.37%

About Rani Therapeutics

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.
Organization
Rani Therapeutics
Employees
140
CEO
Mr. Talat Imran
Industry
Miscellaneous

Management People of Rani Therapeutics

NameTitle
Mr. Mir A. Imran
Executive Chairman
Mr. Talat Imran
CEO & Director
Mr. Svai S. Sanford
Chief Financial Officer
Dr. Mir Hashim
Chief Scientific Officer
Mr. Alireza Javadi
Vice President of Technical Operations
Mr. Eric Groen J.D.
General Counsel
Ms. Bella Vazquez
Vice President of Human Resources
Ms. Kate McKinley M.B.A.
Chief Business Officer
Ms. Arvinder Dhalla
Vice President of Clinical Development

Important FAQs about investing in RANI Stock from India :

What is Rani Therapeutics share price today?

Rani Therapeutics share price today stands at $1.54, Open: $1.45 ; Previous Close: $1.43 ; High: $1.54 ; Low: $1.44 ; 52 Week High: $8.75 ; 52 Week Low: $1.24.

The stock opens at $1.45, after a previous close of $1.43. The stock reached a daily high of $1.54 and a low of $1.44, with a 52-week high of $8.75 and a 52-week low of $1.24.

Can Indians buy Rani Therapeutics shares?

Yes, Indians can invest in the Rani Therapeutics (RANI) from India.

With INDmoney, you can buy Rani Therapeutics at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Rani Therapeutics at zero transaction cost.

How can I buy Rani Therapeutics shares from India?

It is very easy to buy Rani Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Rani Therapeutics (RANI) be purchased?

Yes, you can buy fractional shares of Rani Therapeutics with INDmoney app.

What are the documents required to start investing in Rani Therapeutics stocks?

To start investing in Rani Therapeutics, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Rani Therapeutics Stock (RANI)?

Today’s highest price of Rani Therapeutics (RANI) is $1.54.

Today’s lowest price of Rani Therapeutics (RANI) is $1.44.

What is today's market capitalisation of Rani Therapeutics?

Today's market capitalisation of Rani Therapeutics RANI is 86.1M

What is the 52 Week High and Low Range of Rani Therapeutics Stock (RANI)?

  • 52 Week High

    $8.75

  • 52 Week Low

    $1.24

What are the historical returns of Rani Therapeutics (RANI)?

  • 1 Month Returns

    5.15%

  • 3 Months Returns

    -47.62%

  • 1 Year Returns

    -61.46%

  • 5 Years Returns

    -87%

Who is the Chief Executive Officer (CEO) of Rani Therapeutics ?

Mr. Talat Imran is the current Chief Executive Officer (CEO) of Rani Therapeutics.